Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts

British Journal of Haematology
Anita RethmeierPeter Hokland

Abstract

Silencing of the putative tumour suppressor gene retinoic acid receptor beta2 (RARbeta2) caused by aberrant promoter hypermethylation has been identified in several solid tumours. In order to evaluate the extent of RARbeta2 hypermethylation and transcription in acute myeloid leukaemia (AML) at diagnosis, 320 patients were investigated by bisulphite-denaturing gradient gel electrophoresis and mRNA transcription levels were analysed in 61 of these by quantitative real-time polymerase chain reaction. The results were compared with demographic- and molecular data from the patients. While RARbeta2 was unmethylated in 10/10 bone marrow and 7/7 blood samples from healthy individuals, the gene was hypermethylated in 43% of the AML patients. The RARbeta2 degree of promoter methylation differed between and within individuals, and the mRNA transcription levels of the gene varied inter-individually by a factor of 4000. A significant inverse correlation between promoter hypermethylation and gene expression could be established (t-test, P = 0.019). Comparison of methylation data with a series of other molecular alterations in the same patient materials revealed a correlation between hypermethylation of the RARbeta2 promoter and the presence ...Continue Reading

References

Dec 1, 1994·Current Opinion in Cell Biology·J M Love, L J Gudas
Feb 25, 1996·Experimental Cell Research·S P SiM Peacocke
Jul 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J BérardW E Bradley
Feb 1, 1997·BioTechniques·L CremonesiC Gelfi
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Mar 16, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·A ToulouseW E Bradley
Nov 25, 2000·British Journal of Haematology·F M Abu-DuhierJ T Reilly
Apr 21, 2001·Blood·M ToyotaJ P Issa
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·Y YuanD E Zhang
Mar 21, 2002·Nature Reviews. Cancer·L Altucci, H Gronemeyer
Apr 12, 2002·BMC Cancer·Tatyana IvanovaNatalia Kisseljova
Jul 16, 2002·Carcinogenesis·Esteban Ballestar, Manel Esteller
Sep 17, 2002·Science·Manel EstellerJames G Herman
Oct 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Manel Esteller
Jan 17, 2004·Cancer Biology & Therapy·Shi-Yong Sun
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Reuben Lotan, Yair Lotan
Nov 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yoshio TomizawaMasatomo Mori
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiao-Fei WangRoberto Pili
Jun 17, 2005·Annals of the New York Academy of Sciences·Ulrich SteidlRalf Kronenwett
Aug 18, 2005·European Journal of Haematology·Lene Hyldahl OlesenPeter Hokland
Oct 19, 2005·Annals of Hematology·Oliver GalmRainhardt Osieka
Nov 17, 2005·Molecular and Cellular Biology·Mingqiang RenNicoletta Sacchi
Nov 24, 2005·Journal of Medicinal Chemistry·Birgitte W LundRoger Olsson

❮ Previous
Next ❯

Citations

Apr 28, 2007·The Cancer Journal·Tamer E FandySteven D Gore
Aug 10, 2007·British Journal of Haematology·Rikio SuzukiKiyoshi Ando
May 11, 2007·British Journal of Haematology·Jacqueline Boultwood, James S Wainscoat
Apr 16, 2008·European Journal of Haematology·Lykke GrubachMette Ostergaard
Feb 15, 2012·Pediatric Blood & Cancer·Caroline Juhl-ChristensenPeter Hokland

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.